Could a pill end motion sickness for good?
NCT ID NCT06138613
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests an oral drug called tradipitant in 705 adults with a history of motion sickness. The goal is to see if it is safe and can ease symptoms during real travel. Participants take the drug before or during trips, and researchers monitor side effects and how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tradipitant (oral capsule)
- What this could lead to
- If it works, this could provide a new medication option to prevent or reduce motion sickness during travel.
- What could go wrong
- This is an open-label study (no placebo), so results may be biased. It is still experimental, and side effects or lack of effectiveness are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MOTION SICKNESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Santa Monica Clinical Trials
Santa Monica, California, 90404, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your balance predict motion sickness? new study investigates
- Eye exercises may cure computer sickness
- Can VR make stroke patients sick? new study investigates
- New device trains your head to beat motion sickness
- Shoulder surgery patients may keep arm movement with Just-Right painkiller dose
- Shock therapy for motion sickness? new device zaps nausea away